Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6412 posts found.

FDA approves BioMarin’s Roctavian for adults with severe haemophilia A

June 30, 2023 Medical Communications BioMarin, FDA, Haematology, Roctavian, haemophilia

Global biotechnology company BioMarin Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved Roctavian (valoctocogene roxaparvocec-rvox) …
News

First cellular therapy for patients with type 1 diabetes approved by FDA

June 29, 2023 Medical Communications Diabetes, FDA, Lantidra, Type 1 diabetes, diabetes

The US Food and Drug Administration (FDA) has announced that it has approved Lantidra, the first allogeneic (donor) pancreatic islet …
News

Microba commences phase 1 clinical trial for IBD drug

June 28, 2023 Medical Communications Biotherapeutic, Gastrointestinal tract, Microba, clinical trials, ibd

Australian precision microbiome company Microba has announced that the first participants in its phase 1 inflammatory bowel disease (IBD) clinical …
News

Astellas Pharma shares positive results from phase 3b trial of Fezolinetant for menopause symptoms

June 28, 2023 Medical Communications Astellas Pharma, Pharmacy, clinical trial, fezolinetant, menopause

Astellas Pharma has announced positive topline results from the phase 3b DAYLIGHT clinical trial for fezolinetant, its investigational oral, nonhormonal …
News

Bristol Myers Squibb’s Sotyktu recommended for NHS use for adult patients with psoriasis

June 28, 2023 Medical Communications Dermatology, NHS, Sotyktu, bristol myers squibb, psoriasis

Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Sotyktu (deucravacitinib) …
News

UK nonprofit National Cancer Research Institute to close

June 27, 2023 Medical Communications Cancer, NCRI, National Cancer Research Institute, Oncology, oncology

The National Cancer Research Institute (NCRI) has announced that it is closing after 22 years of advancing cancer research. Established …
News

AstraZeneca’s Xigduo XR approved in China for adults with type-2 diabetes

June 27, 2023 Medical Communications AstraZeneca, China, Diabetes, Xigduo XR, diabetes

AstraZeneca has announced that its Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has now been approved …
News

FDA approves Pfizer’s Litfulo for patients with severe alopecia areata

June 26, 2023 Medical Communications FDA, Litfulo, Pfizer, Pharmacy, alopecia, alopecia areata

Pfizer has announced that the US Food and Drug Administration (FDA) has approved its Litfulo (ritlecitinib) for patients over the …
News

AstraZeneca’s Soliris given EU CHMP recommendation for marketing authorisation

June 26, 2023 Medical Communications AstraZeneca, CHMP, EMA, Immunology, soliris

UK-based biopharmaceutical company AstraZeneca has announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) …
News

CHMP gives positive opinion recommending authorisation to GSK’s CKD drug

June 26, 2023 Medical Communications CKD, EMA, Nephrology

Global biopharmaceutical company GSK has announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) …
News

GSK settles first Zantac lawsuit due for trial in US

June 23, 2023 Medical Communications Cancer, GSK, Pharmacy, Zantac, lawsuit

UK-based pharmaceutical and biotechnology company GSK has reached a settlement with a US man who claims the drugmaker’s heartburn medicine …
News

FDA approves new medicines to treat paediatric type 2 diabetes

June 22, 2023 Medical Communications Diabetes, FDA, Synjardy, jardiance, paediatrics, type 2 diabetes

The US Food and Drug Administration (FDA) has announced that it has approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin …
News

FDA approves Pfizer’s HRR mCRPC drug

June 21, 2023 Medical Communications FDA, Oncology, Pfizer, breast cancer, oncology, prostate cancer

US-based pharmaceutical and biotechnology company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its homologous …
News

PharmaTher and Vitruvias sign collaboration agreement to commercialise ketamine-based treatment in the US

June 21, 2023 Medical Communications Ketamine, Neurology, PharmaTher, Vitruvias, commercialisation

Specialty pharmaceutical companies, Canadian PharmaTher and US-based Vitruvias, have entered into a commercialisation partnership to bring Ketarx products to the …
News

Abu Dhabi’s Department of Health, M42 and AbbVie enter strategic partnership

June 20, 2023 Medical Communications AbbVie, Abu Dhabi, DoH, M42, Oncology, strategic partnership

Abu Dhabi’s Department of Health (DoH) has signed a Memorandum of Understanding (MoU) with AbbVie and M42 to advance research …
News
The Gateway to Local Adoption Series

Latest content

InnoScot highlights NHS Scotland’s progress towards net zero healthcare

August 11, 2026

NHS England approves delayed-release treatment for rare kidney disease

August 10, 2026

Product value to pathway impact: What the CVD Modern Service Framework means for pharma

August 9, 2026

Functional lung imaging offers new possibilities for respiratory care

August 9, 2026

Five Facts about cardiovascular disease

August 9, 2026